Veracyte Inc., a global cancer diagnostics company listed on the Nasdaq under the ticker symbol VCYT, announced it will participate in two major investor conferences in late summer and early autumn 2026. The engagements aim to provide investors with updates on the company’s business strategy and pipeline developments through scheduled fireside chats.

The first engagement is set for Tuesday, Aug. 11, at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Veracyte representatives will take part in a fireside chat beginning at 10:30 a.m. Eastern Time. This event offers an early opportunity for stakeholders to engage with management ahead of the broader healthcare sector calendar.

Conference Schedule

The second appearance will occur at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The fireside chat is scheduled for Tuesday, Sep. 15, at 5:35 p.m. Eastern Time. These presentations are standard components of the company’s quarterly investor relations cycle, designed to maintain transparency with shareholders and analysts.

Live audio webcasts of both sessions will be streamed on Veracyte’s official investor relations website at http://investor.veracyte.com/events-presentations . For those unable to attend live, replays of the webcasts will remain available for 90 days following each broadcast. This extended availability ensures that institutional and retail investors can review the discussions at their convenience.

What the Numbers Show

While this announcement contains no financial metrics, the timing of these conferences aligns with typical periods when biotech and diagnostics firms update markets on clinical trial progress or commercial adoption rates. Veracyte’s portfolio includes key genomic tests such as the Afirma Genomic Sequencing Classifier, Decipher Bladder and Prostate Genomic Classifiers, Prosigna Breast Risk of Recurrence test, and TrueMRD Monitoring Test for MIBC. Investor sentiment during these calls often hinges on commentary regarding reimbursement landscapes and hospital uptake for these specific assays.

Piper Sandler analyst David Westenberg has initiated coverage on Veracyte Inc with an Overweight rating and announced a price target of $66. Veracyte shares closed at $56.62 on Tuesday. This new recommendation contrasts with a recent outlook from Morgan Stanley, where analyst Tejas Savant maintained an Underweight rating while raising the price target to $47 from $37. Veracyte trades on the NASDAQ under the ticker symbol VCYT.

Analyst Ratings and Price Targets

The initiation by Piper Sandler provides a bullish perspective on the company's future performance. Meanwhile, Morgan Stanley's revised valuation acknowledges potential upside but maintains a cautious stance relative to broader market peers.

The divergence in ratings highlights differing views on Veracyte's risk-reward profile. Investors should consider the varying price targets and recommendations when evaluating their positions in the genomic diagnostics company.